KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Regeneron Pharmaceuticals (REGN) Tax Provisions (2016 - 2025)

Regeneron Pharmaceuticals (REGN) has 14 years of Tax Provisions data on record, last reported at $199.1 million in Q4 2025.

  • For Q4 2025, Tax Provisions rose 392.82% year-over-year to $199.1 million; the TTM value through Dec 2025 reached $725.8 million, up 97.6%, while the annual FY2025 figure was $725.8 million, 97.6% up from the prior year.
  • Tax Provisions reached $199.1 million in Q4 2025 per REGN's latest filing, down from $303.3 million in the prior quarter.
  • Across five years, Tax Provisions topped out at $653.9 million in Q2 2021 and bottomed at -$455.7 million in Q4 2022.
  • Average Tax Provisions over 5 years is $114.9 million, with a median of $112.8 million recorded in 2022.
  • Peak YoY movement for Tax Provisions: soared 2927.31% in 2021, then tumbled 152.99% in 2024.
  • A 5-year view of Tax Provisions shows it stood at $653.9 million in 2021, then tumbled by 169.69% to -$455.7 million in 2022, then soared by 97.37% to -$12.0 million in 2023, then skyrocketed by 436.67% to $40.4 million in 2024, then soared by 392.82% to $199.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Tax Provisions were $199.1 million in Q4 2025, $303.3 million in Q3 2025, and $127.1 million in Q2 2025.